David G. Maloney, MD, PhD
When I was a student at Stanford University in the 1980s, I was part of a team that made an amazing discovery. We created a protein called a monoclonal antibody that targeted cancer cells without harming healthy ones. At the time, there were a lot of skeptics — most people thought that antibody research wasn’t worthwhile. But we persevered, and now monoclonal antibodies are an important part of therapy for a variety of cancers. That breakthrough made me hungry for more. What else could I discover about the immune system? Could we train it to go after tumors the same way it attacks viruses? Does it hold the key for curing cancer, once and for all? These are the questions that have driven my work.
A treatment plan isn’t something that we devise in one short discussion. It’s an in-depth conversation that may stretch across multiple visits. We’ll consider factors such as your health, your age, your disease, your personal philosophy and what the latest research has to offer. Treatments are rapidly evolving, and I enjoy sharing these advances with you so that you can make the best decisions about your care. Whatever you choose, I’m dedicated to helping you achieve the best possible outcome.
Specialty: Medical Oncology
As the medical director of the Bezos Family Immunotherapy Clinic at SCCA, I treat patients with lymphoid cancers, such as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma and multiple myeloma. My expertise spans the use of antibodies (proteins in the immune system that fight invaders), vaccines and bone marrow transplants. In the 1990s, I led the development of the drug rituximab, the first antibody-based cancer treatment, and I was also part of the team that created the mini-transplant, a less intense form of the conventional stem cell transplant.
Today, my research is focused on developing new immunotherapies where a patient’s own T cells (immune cells) are modified with a molecule called a chimeric antigen receptor (CAR). This receptor directs a patient’s immune system to attack tumors. Known as CAR T-cell therapy, this approach has been remarkably effective in early-phase trials, even with very advanced cancers that resist other treatments.
CAR T-cell therapy for leukemia and lymphoma patients can be an incredibly effective treatment. That means understanding when to refer a patient for treatment is critical.
As survival rates for lymphoma are improving, the first therapy is typically the most effective and important. But patients may need more than one therapy. SCCA has one of largest and most comprehensive multidisciplinary lymphoma teams in the nation, and the largest team in the Northwest.
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.
SCCA’s David Maloney, MD, Ph.D. spoke with Oncology Nursing News about the newly standardized grading criteria to help regulate CAR T-cell therapy.
SCCA’s Dr. David G. Maloney discussed how newly standardized grading criteria is integral to managing toxicity levels in cellular immunotherapy.
Your care team
SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.